hVIVO, part of Open Orphan plc, is the world leader in the testing of vaccines and antivirals using human challenge study clinical trials and is led by an experienced Leadership team.
Please see some useful resources below including the latest Open Orphan plc investor presentation, approved company descriptions, and images which can be used for editorial purposes as long as the connection to Open Orphan / hVIVO / Venn is clearly recognisable. Commercial use is prohibited.
Visit our Company News page to see more recent Company Announcements and please contact carol.dalton@openorphan.com if you require any further information or wish to schedule an interview.
Presentations
| TITLE | DATE | SIZE | DOWNLOAD |
|---|---|---|---|
| Open Orphan Investor Presentation | 30.09.20 | 2.0MB |
Images – hVIVO
| IMAGE | TITLE | SIZE | DOWNLOAD |
|---|---|---|---|
 |
Cathal Friel – Executive Chairman Open Orphan plc | 12.4 MB | JPG |
 |
Dr Andrew Catchpole – hVIVO Chief Scientist | 6.6 MB | JPG |
 |
Adam French – hVIVO Director Laboratory Operations | 9.8 MB | JPG |
 |
Danny Smith – Director of Volunteer Engagement & Retention | 9.6 MB | JPG |
 |
FluCamp Nurse 1 | 16.7 MB | JPG |
 |
FluCamp Nurse 2 | 14.7 MB | JPG |
 |
FluCamp Nurse 3 | 20.5 MB | JPG |
 |
Nurse with sample | 1.5 MB | JPG |
 |
hVIVO FluCamp 1 | 110kb | JPG |
 |
hVIVO FluCamp 2 | 288kb | JPG |
 |
hVIVO FluCamp 3 | 16.1 MB | JPG |
 |
hVIVO FluCamp 4 | 1.6 MB | JPG |
 |
hVIVO Lab 1 | 20.9 MB | JPG |
 |
hVIVO Lab 2 | 9 MB | JPG |
 |
hVIVO Lab 3 | 18.7 MB | JPG |
 |
hVIVO Lab 4 | 17.2 MB | JPG |
 |
FluCamp Volunteer 1 | 23.2 MB | JPG |
Company Logos
| FILE | TITLE | SIZE | DOWNLOAD |
|---|---|---|---|
 |
hVIVO Logo | 29KB | PNG |
 |
Open Orphan Logo | 157KB | PNG |
 |
Venn Life Sciences Logo | 126KB | JPG |
 |
Flucamp Logo | 31KB | PNG |
Approved Company Descriptions
Open Orphan – 75 words
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe’s only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development.For more information please visit our Company Overview page
Open Orphan – 150 words
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe’s only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development.
The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines.
Open Orphan comprises of two commercial specialist CRO services businesses (hVIVO and Venn) and is developing an early stage orphan drug genomics data platform business.
For more information please visit our Company Overview page
Press Releases
| TITLE | DATE | SIZE | DOWNLOAD |
|---|---|---|---|
| Press Launch of hVIVO COVID Clear Test | 04.06.20 | 267KB |